Iambic Therapeutics to Present IAM1363 Poster at 2024 ASCO Meeting
Iambic Therapeutics, a biotechnology firm at the clinical stage, is making strides in developing innovative therapeutics through its AI-driven discovery framework. The company recently announced an upcoming poster presentation on its Phase 1 study of IAM1363, a selective inhibitor of HER2 signaling that can penetrate the brain, aimed at treating HER2-driven cancers. The presentation will be featured at the American Society for Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.
IAM1363 is designed to target both wild-type and oncogenic mutant HER2 proteins, providing a broader therapeutic window compared to current HER2 inhibitors. Unlike other treatments, IAM1363 avoids the toxic effects that come from off-target inhibition of EGFR. Preclinical research has shown that IAM1363 offers over 1000-fold selectivity for HER2 over EGFR, which contributes to a promising pharmacokinetic and safety profile. Additionally, the drug exhibits preferential tumor enrichment and the ability to penetrate the central nervous system. In various HER2 tumor models, including those affecting the brain, IAM1363 has shown better efficacy and tolerability compared to existing tyrosine kinase inhibitors and HER2-targeted antibody-drug conjugates. This drug was discovered using Iambic's AI-driven platform and is currently undergoing evaluation in a Phase 1 clinical trial, IAM1363-01 (NCT06253871).
The details of the poster presentation are as follows:
Title: IAM1363-01: A Phase 1/1b Study of a Selective and Brain-Penetrant HER2 Inhibitor for HER2-driven Solid Tumors
Abstract Number: TPS3186
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Location: Hall A, Poster board 318a
Date and Time: June 1, 9:00 am-12:00 pm CT
Presenter: Alex A. Adjei, MD, PhD, FACP, Chief of the Cleveland Clinic’s Cancer Institute
Founded in 2019 and based in San Diego, California, Iambic Therapeutics is a burgeoning force in the biotech industry. The company leverages its groundbreaking AI-driven drug discovery platform to revolutionize the development of new medicines. Iambic has built a top-tier team combining AI specialists and seasoned drug developers with proven success in bringing clinically validated therapeutics to fruition. The Iambic platform is noted for its ability to deliver high-quality, innovative therapeutics to the clinical stage with remarkable speed, addressing a wide array of target classes and mechanisms of action. The company is currently advancing its own pipeline of clinical assets to meet urgent, unmet medical needs.
Iambic Therapeutics epitomizes the synergy between advanced technology and pharmaceutical expertise, pushing the boundaries of what is possible in drug discovery and therapeutic development. The unique AI-driven platform at the core of Iambic's operations enables rapid and precise identification of potential drug candidates, setting a new benchmark in the biotech industry. As the company continues to progress through its clinical trials, the medical community and patients alike anticipate the potential breakthroughs that could emerge from Iambic's pioneering efforts.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
